MS-N318 · Exercise and rehabilitation · Bone health · Prostate cancer · Human evidence · Appraised 12 November 2026

Can impact-loading and resistance exercise prevent bone loss in men receiving androgen-deprivation therapy for prostate cancer?

Evidence at a glance

• Evidence label: Several randomized trials; mixed and generally modest bone-density effects, with no fracture-prevention evidence
• Benefit: Some trials attenuated lumbar-spine or femoral-neck loss, but others found no average hip or spine benefit; strength and mobility improved more consistently.
• Certainty: Low to moderate for small site-specific bone-density effects; insufficient for preventing fractures.
• Risk: Carefully screened programs were generally feasible, but impact loading can be inappropriate with bone metastases, severe osteoporosis, falls risk or joint disease.

What was studied

Targeted exercise: Trials used supervised progressive resistance plus weight-bearing or impact exercise, sometimes with aerobic training or protein, calcium and vitamin D. Program durations ranged from six to 12 months.

Key populations: One trial randomized 154 men on ADT to impact-plus-resistance, aerobic-plus-resistance or delayed aerobic exercise. Other trials randomized 104 men starting ADT, 70 men to exercise plus nutrition versus usual care, and 51 men to impact-plus-resistance versus stretching.

What the evidence found

In 154 men, impact plus resistance attenuated loss at the spine and femoral neck versus delayed aerobic exercise (about −1% vs −2%) and improved muscle strength by 9%–34%; the sample was well functioning.

In 104 men starting ADT, six months of immediate supervised resistance, aerobic and impact exercise largely preserved lumbar-spine density versus delayed exercise (−0.4% vs −1.6%) and preserved lean tissue, but whole-body, spine and hip bone density still declined over time and fat increased.

In 70 men, exercise plus whey protein, calcium and vitamin D did not improve primary hip or spine density in intention-to-treat analysis. Exercise adherence was 56% and supplement adherence 77%. A per-protocol femoral-neck signal among adherent participants is vulnerable to selection bias.

In 51 men, one year of impact plus resistance did not improve average hip or L1–L4 spine density versus stretching; a single-vertebra L4 finding favored exercise. No study-related injury was reported. Across these trials, fracture reduction was not demonstrated.

How to interpret it

The most consistent gains are strength and function. Bone-density findings vary by skeletal site, program, timing and adherence, and are too small or inconsistent to substitute for formal fracture-risk assessment or indicated medication.

Calcium, vitamin D and protein are not automatically beneficial at high doses. The nutrition-combination trial’s negative primary result and modest adherence are important.

Practical safety context

Before impact loading, assess bone metastases, prior fractures, DXA results, osteoporosis medication, balance, neuropathy, joint disease, cardiovascular risk and technique. Programs may need to omit impact work or use physical-therapy supervision.

Calcium and vitamin D dosing should reflect diet, blood levels, kidney stones, kidney function and other medications. Exercise does not replace antiresorptive therapy when guideline-based fracture risk warrants it.

Questions for the care team

• What is my baseline fracture risk and have I had a DXA scan?
• Are there bone metastases or orthopedic issues that make impact loading unsafe?
• Do I need medication, calcium or vitamin D based on measured risk rather than a generic supplement plan?

Funding and conflicts

Funding and conflicts varied across the four trials and were not completely verified in one consistent source. The record therefore does not assume industry independence; individual reports should be checked when decisions depend on a specific program.

Sources

• Exercise-mode bone-density trial, n=154 (PMID 30395051)
• Immediate versus delayed exercise at ADT initiation, n=104 (PMID 30239116)
• Exercise plus nutrition IMPACT trial, n=70 (PMID 33867499)
• POWIR impact-plus-resistance trial, n=51 (PMID 24500540)
• Systematic review of feasibility and safety through June 2021

Last literature search: 12 November 2026. Record appraisal: 12 November 2026. PubMed records, one full trial report and the safety review were appraised; where only abstracts were accessible, unreported details are marked rather than inferred. This page is educational and does not replace individualized medical advice. These supportive-care outcomes do not establish tumor shrinkage, delayed recurrence or longer survival.